QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript
QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.
How this was made

The 30-second read
Why it matters
The call combines a quantified earnings snapshot (Q3 revenue down 12% YoY) with forward-looking operational guidance (continued China destocking through 2026, increased pricing pressure in 2027) and a quantified cost program (>$80M annual savings in 2027, $30M-$35M restructuring charges in 4Q26).
Market read
Traders can update estimates for margins and free cash flow using the disclosed restructuring savings and charges, while also pricing ongoing China and respiratory demand headwinds into 2026-2027.
What to watch
Provincial implementation timing uncertainty in China could extend volatility; also, the magnitude and cash timing of restructuring charges ($30M-$35M, mostly in 4Q26) can pressure near-term free cash flow despite longer-term savings.
Background
QuidelOrtho is restructuring its operating model into two focused businesses, core diagnostics and point-of-care diagnostics, while winding down U.S. donor screening and navigating China IVD pricing guideline changes.
Ticker impact
QuidelOrtho reports Q3 revenue down 12% YoY and guides continued China destocking, while announcing a cost transformation targeting $80M+ annual savings in 2027.
Likely mixed reaction, with downside risk from China/respiratory softness offset by upside from quantified restructuring savings and restructuring charges.
The transcript includes specific Q3 revenue declines, China destocking and 2027 pricing pressure, plus quantified restructuring savings and restructuring charge timing, which are direct inputs to near-term estimates and longer-term margin/cash-flow models.
Market effects
Diagnostic and point-of-care peers may face read-through on China IVD pricing guideline impacts and margin pressure versus cost actions.
China revenue decline and distributor destocking expectations highlight ongoing demand softness and pricing pressure into 2027.
Outside China, labs and immunohematology growth suggests resilience that could influence sentiment toward global in-vitro diagnostics demand.
Counterpoint
The $80M+ 2027 savings may not fully offset near-term revenue declines if China destocking and 2027 pricing pressure persist longer than management’s assumptions.
Key entities
- companyQuidelOrtho
Subject of the earnings call transcript, reporting Q3 results and announcing a cost transformation and enterprise restructuring program.
- regulatory/policyChina nationwide IVD pricing guidelines
Policy change driving distributor and customer destocking, with provincial implementation timing uncertain.
- product/platformNULEXA
Point-of-care molecular platform discussed as early in launch with menu expansion opportunities.
- product/platformVITROS 450
Labs analyzer launch expansion to additional international markets mentioned as part of innovation investment.


